- Report
- January 2023
- 197 Pages
Global
From €4925EUR$5,281USD£3,950GBP
- Report
- March 2022
- 120 Pages
Global
From €2413EUR$2,500USD£2,003GBP
- Report
- April 2023
- 90 Pages
Global
From €4585EUR$4,750USD£3,806GBP
- Report
- November 2021
- 90 Pages
Global
From €4344EUR$4,500USD£3,606GBP
- Report
- March 2020
- 136 Pages
Global
From €3074EUR$3,185USD£2,552GBP
€4392EUR$4,550USD£3,646GBP
- Report
- April 2023
- 175 Pages
Global
€4628EUR$4,795USD£3,842GBP
- Report
- January 2023
- 232 Pages
Global
From €5309EUR$5,500USD£4,407GBP
- Report
- October 2021
- 103 Pages
United States
From €2654EUR$2,750USD£2,203GBP
€5309EUR$5,500USD£4,407GBP
- Training
- 60 Minutes
Global
- Report
- July 2023
- 101 Pages
Global
From €3500EUR$3,884USD£3,007GBP
- Report
- May 2022
- 98 Pages
Global
From €3500EUR$3,884USD£3,007GBP
- Report
- February 2022
- 107 Pages
Global
From €3200EUR$3,551USD£2,749GBP
- Report
- October 2024
- 79 Pages
Global
From €3500EUR$3,884USD£3,007GBP
- Report
- August 2023
- 83 Pages
Global
From €3500EUR$3,884USD£3,007GBP
- Report
- November 2022
Global
From €4826EUR$5,000USD£4,006GBP
- Report
- May 2022
- 71 Pages
Global
From €1930EUR$2,000USD£1,602GBP
- Book
- April 2024
- 256 Pages
The Biodefense market is a sector of the biotechnology industry that focuses on the development of products and services to protect against biological threats. This includes the development of vaccines, diagnostics, and treatments for infectious diseases, as well as the development of countermeasures to protect against bioterrorism. Biodefense products are designed to protect against a wide range of biological agents, including bacteria, viruses, and toxins.
The Biodefense market is driven by the need to protect against the increasing threat of biological agents, as well as the need to develop treatments for existing and emerging infectious diseases. Governments, healthcare organizations, and private companies are investing in the development of biodefense products and services.
Some of the major companies in the Biodefense market include Emergent BioSolutions, GlaxoSmithKline, Johnson & Johnson, Merck, Novavax, Pfizer, and Sanofi. These companies are developing a range of products and services to protect against biological threats, including vaccines, diagnostics, and treatments. Show Less Read more